BackPhio Pharmaceuticals - Warrants (21/12/2021) Overview

Phio Pharmaceuticals - Warrants (21/12/2021) Long Term Debt

Phio Pharmaceuticals - Warrants (21/12/2021)'s long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) Long Term Debt History

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) vs. peers: Long Term Debt Comparison

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) (PHIOW) FAQ

Phio Pharmaceuticals - Warrants (21/12/2021)'s long-term debt stands at $0 as of March 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Phio Pharmaceuticals - Warrants (21/12/2021) reported $0 in long-term debt versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Phio Pharmaceuticals - Warrants (21/12/2021)'s long-term debt evolved across reporting periods, while the comparison chart places PHIOW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. Phio Pharmaceuticals - Warrants (21/12/2021)'s reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.